NIKKEI 225
27,131.34 0.00 (0.00%) HANG SENG
24,243.61 -412.85 (-1.67%) CRUDE OIL
85.31 -0.29 (-0.34%) GOLD FUTURES
1,849.60 -2.90 (-0.16%) DOW
34,297.73 -66.77 (-0.19%) BTC-GBP
27,308.44 +88.11 (+0.32%)
Spexis AG (PPHOF)
| Previous close | 2.5000 |
| Open | 2.5000 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 2.5000 - 2.5000 |
| 52-week range | 2.5000 - 8.6626 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 28.891M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.9800 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
Polyphor closes merger with EnBiotix and is renamed Spexis
Polyphor AG / Key word(s): Merger30-Dec-2021 / 07:15 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland, December 30, 2021Polyphor closes merger with EnBiotix and is renamed SpexisPolyphor AG (SIX: POLN) and EnBiotix Inc. today announced the closing of the merger of the two companies and the change of name of the combined company to Spexis AG. Pursua
- EQS Group
Polyphor to inform about the financing of its merger partner EnBiotix
Polyphor AG / Key word(s): Merger/Financing29-Dec-2021 / 07:30 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland, December 29, 2021Polyphor to inform about the financing of its merger partner EnBiotix Polyphor AG (SIX: POLN) and EnBiotix Inc. today announced that EnBiotix has completed a convertible debenture raise of USD 11 million to finance its f
- EQS Group
Polyphor and EnBiotix announce dosing of first patient in a first-in-human clinical trial of inhaled murepavadin
Polyphor AG / Key word(s): Study15-Dec-2021 / 07:15 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland, December 15, 2021Polyphor and EnBiotix announce dosing of first patient in a first-in-human clinical trial of inhaled murepavadin Polyphor AG (SIX: POLN) and EnBiotix Inc. today announced that the first subjects have been dosed in the first-in-huma
